Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash from Investing Activities: 2014-2025

Historic Cash from Investing Activities for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$61,960.

  • Ascendis Pharma A's Cash from Investing Activities rose 88.78% to -$61,960 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year decrease of 140.73%. This contributed to the annual value of $7.4 million for FY2024, which is 97.59% down from last year.
  • As of Q3 2025, Ascendis Pharma A's Cash from Investing Activities stood at -$61,960, which was up 98.74% from -$4.9 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Cash from Investing Activities peaked at $226.1 million during Q1 2023, and registered a low of -$128.0 million during Q4 2021.
  • Moreover, its 3-year median value for Cash from Investing Activities was $654,748 (2024), whereas its average is $28.2 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Cash from Investing Activities surged by 980.06% in 2023, and later tumbled by 849.97% in 2025.
  • Ascendis Pharma A's Cash from Investing Activities (Quarterly) stood at -$128.0 million in 2021, then spiked by 99.36% to -$813,137 in 2022, then spiked by 980.06% to $7.2 million in 2023, then crashed by 105.73% to -$410,341 in 2024, then soared by 88.78% to -$61,960 in 2025.
  • Its last three reported values are -$61,960 in Q3 2025, -$4.9 million for Q2 2025, and -$739,475 during Q1 2025.